Clinical trial

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

NCT06263543

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-06-17

PhasePHASE2

Study timeline

Study start (actual)2024-06-17Date precision: day

Registry last updated2026-08-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Metastatic Breast Cancerunresolved

Advanced Breast Cancerunresolved

Hormone-receptor-positive Breast Cancerunresolved

Human Epidermal Growth Factor 2 Low Breast Cancerunresolved

Interventions

Sacituzumab govitecanDRUG · verified · RxNorm: sacituzumab govitecan

Sponsors & collaborators

Reshma L. Mahtani, D.O.lead sponsor

Gilead Sciencescollaborator

Mapped research locations

AtlantaGeorgia, United States1 MiamiFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06263543 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.